BioSpace News Archive

Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, announced that Matt Bond has become its chief financial officer.

Anixa Biosciences, Inc. today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent Number 11,786,489, which broadens protection of Anixa’s novel ovarian cancer vaccine technology.

DarioHealth Corp., a leader in the global digital health market, announced that it will host an in-person investor day in New York at the offices of Sullivan & Worcester LLP located at 1633 Broadway, 32nd floor, on October 17, 2023 at 11:00 AM ET.

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx) today announced that it is advancing Niyad™ (a lyophilized formulation of nafamostat) into a registrational study following the recent approval of an Investigational Device Exemption (IDE) submission to the United States Food and Drug Administration (FDA).

Biotricity, Inc. today announced the filing of a patent application for its groundbreaking Biotres device.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) today announces that its registration-enabling pivotal Phase 3 study of its lead clinical candidate, Bria-IMT™, in combination with an immune check point inhibitor, is fully approved by the Institutional Review Board (IRB) and will soon enroll patients with advanced metastatic breast cancer.

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the dosing of the first patient in its theranostic 64Cu/67Cu SAR-Bombesin Phase I/II trial in metastatic castrate resistant prostate cancer (mCRPC).

Akura Medical, a Shifamed portfolio company focused on a differentiated approach to effectively address the major challenges of venous thromboembolism (VTE), announced today the closing of its $35M Series B financing.

ZeptoMetrix® is pleased to announce it has been awarded an IVDR Quality Management System certificate from British Standards Institution BSI, NB 2797, one of the notified bodies under the new EU In Vitro Diagnostics Regulation.

BioMed Realty, a leading provider of real estate solutions to the life science and technology industries, announced the appointment of Marie Lewis to Executive Vice President and General Counsel.